Skip to content
EntityQ15708292· pop 6· linked from 224 articles

cobimetinib

Sign in to save

Also known as GDC-0973, XL-518, XL518, GDC 0973, RG 7420, Xl 518, RG7420, GDC0973

Cobimetinib, sold under the brand name Cotellic, is an anti-cancer medication used to treat melanoma and histiocytic neoplasms. Cobimetinib is a MEK inhibitor. Cobimetinib is marketed by Genentech.

~3 min read

Encyclopedic overview

5 sections
Contents
  • Medical use
  • Adverse effects
  • History
  • Research
  • References

Cobimetinib, sold under the brand name Cotellic, is an anti-cancer medication used to treat melanoma and histiocytic neoplasms. Cobimetinib is a MEK inhibitor. Cobimetinib is marketed by Genentech.

The most common side effects include diarrhea, rash, nausea (feeling sick), vomiting, pyrexia (fever), photosensitivity (light sensitivity) reaction, abnormal results for certain liver function tests (increased levels of alanine aminotransferase, aspartate aminotransferase) and abnormal results for an enzyme related to muscle breakdown (creatine phosphokinase).

Excerpted from Wikipedia’s “cobimetinib” article, available under the CC BY-SA 4.0 licence.

Available in 6 languages

via Wikidata sitelinks · CC0